Recruitment of healthy volunteers for initial evaluation of ChAdOx1 nCoV-19, a candidate non-replicating adenovirus vaccine developed at the Oxford Vaccine Centre in underway. The same technology platform is being used in an experimental MERS vaccine (study ongoing).
The COVID-19 vacccine study is a placebo-controlled, single dose study (n=560, split evenly but with 10 volunteers receiving two doses), monitored over six months and with an optional 12 month follow-up.
Sanofi Pasteur, already active in COVID-19 protein subunit vaccine development have partnered with Translate Bio, an mRNA technology company which already has 100g scale capability for clinical grade material. The companies will develop several potential candidates over the coming months.
Oxford Vaccine Centre study page https://covid19vaccinetrial.co.uk/ accessed 27th March 2020
Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19. Company press release online 27th March 2020 https://tinyurl.com/yxyymu7x
No comments:
Post a Comment